20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Tarsus Pharmaceuticals Inc (TARS) operates in the BIOTECHNOLOGY industry and is headquartered in Irvine, United States with about 370 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, TARS reported $451M in revenue and ($66M) in net income.
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
Interactive charts & full statements → Open the TARS valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $607M | $451M | $183M | $17M | $26M | $57M | $33M | $0M | $0M |
| Gross Profit | $550M | $421M | $170M | $16M | $25M | $55M | $0M | $0M | $0M |
| Gross Margin % | 90.6% | 93.2% | 93.0% | 90.9% | 96.3% | 96.4% | -0.7% | — | — |
| Operating Income (EBIT) | ($49M) | ($71M) | ($121M) | ($143M) | ($63M) | ($12M) | ($27M) | ($4M) | ($1M) |
| Operating Margin % | -8.1% | -15.7% | -65.9% | -820.5% | -242.9% | -21.3% | -80.7% | — | — |
| Net Income | ($47M) | ($66M) | ($116M) | ($136M) | ($62M) | ($14M) | ($27M) | ($5M) | ($1M) |
| Net Margin % | -7.7% | -14.7% | -63.2% | -778.9% | -240.5% | -24.2% | -80.2% | — | — |
| EBITDA | ($36M) | ($54M) | ($106M) | ($132M) | ($60M) | ($13M) | ($27M) | ($5M) | ($1M) |
| Earnings Per Share (EPS) | $-1.09 | $-1.59 | $-3.07 | $-4.62 | $-2.52 | $-0.67 | $-1.32 | $-0.24 | $-0.31 |
| Shares Outstanding (M) | 43M | 42M | 38M | 29M | 25M | 21M | 20M | — | 4M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $174M | $162M | $152M | $119M | $103M | $78M | $66M | $48M |
| Gross Profit | $162M | $153M | $141M | $94M | $96M | $73M | $61M | $45M |
| Gross Margin % | 93.0% | 94.2% | 92.8% | 79.3% | 93.9% | 93.3% | 92.6% | 93.3% |
| Operating Income (EBIT) | ($20M) | ($6M) | ($8M) | ($15M) | ($22M) | ($26M) | ($24M) | ($25M) |
| Operating Margin % | -11.5% | -3.8% | -5.3% | -12.2% | -21.6% | -33.6% | -36.8% | -52.3% |
| Net Income | ($19M) | ($7M) | ($8M) | ($13M) | ($20M) | ($25M) | ($23M) | ($23M) |
| Net Margin % | -10.7% | -4.3% | -5.5% | -10.6% | -19.8% | -32.1% | -34.8% | -48.7% |
| EBITDA | ($13M) | ($7M) | ($4M) | ($12M) | ($18M) | ($22M) | ($20M) | ($21M) |
| Earnings Per Share (EPS) | $-0.43 | $-0.16 | $-0.20 | $-0.30 | $-0.48 | $-0.64 | $-0.60 | $-0.61 |
| Shares Outstanding (M) | 43M | 43M | 43M | 43M | 42M | 39M | 39M | 38M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $79M | ($12M) | ($83M) | ($117M) | ($49M) | $4M | ($21M) | ($4M) | ($1M) |
| Capital Expenditures (CapEx) | $18M | $10M | $2M | $6M | $1M | $1M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | $62M | ($22M) | ($85M) | ($123M) | ($50M) | $3M | ($22M) | ($4M) | ($1M) |
| FCF Margin % | 10.2% | -4.9% | -46.2% | -705.0% | -191.9% | 5.5% | -64.6% | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $67M | ($25M) | $19M | $18M | ($29M) | ($21M) | ($22M) | ($9M) |
| Capital Expenditures (CapEx) | $4M | $6M | $6M | $2M | $1M | $1M | $5M | $0M |
| Free Cash Flow (FCF) | $63M | ($30M) | $13M | $16M | ($30M) | ($21M) | ($27M) | ($9M) |
| FCF Margin % | 36.0% | -18.8% | 8.6% | 13.8% | -29.6% | -27.1% | -41.0% | -18.6% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $611M | $562M | $377M | $265M | $228M | $179M | $172M | $58M | $2M |
| Cash & Cash Equivalents | $205M | $184M | $95M | $225M | $72M | $171M | $168M | $58M | $2M |
| Total Liabilities | $264M | $219M | $152M | $69M | $35M | $12M | $6M | $64M | $4M |
| Total Debt (Short + Long-Term) | $73M | $72M | $72M | $30M | $20M | $1M | $0M | $0M | $0M |
| Total Shareholders' Equity | $347M | $343M | $225M | $197M | $193M | $167M | $166M | ($6M) | ($1M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TARS viewer.
About TickerBase · Data methodology & sources · Privacy · Terms